Upfront debulking surgery or delayed surgery after neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer: Comparison of survival from a noncancer center in India
Authors:
- Shashank ShekharSSShashank Shekhar
- Pratibha SinghPSPratibha Singh
- Jeewan R VishnoiJVJeewan R Vishnoi
- Shuchita GoelSGShuchita Goel
- Puneet PareekPPPuneet Pareek
- Charu SharmaCSCharu Sharma
- Manu GoyalMGManu Goyal
- Garima YadavGYGarima Yadav
- Manisha JhirwalMJManisha Jhirwal
- Sweta SoniSSSweta Soni
- Sanjeev MisraSMSanjeev Misra
- 7 August 2023
- journal article
- research article
- Published by Medknow in Indian Journal of Cancer
- Vol. 61 (1) , 68-74
Abstract
Background: In advanced-stage epithelial ovarian cancer (EOC) standard of care is upfront debulking surgery (UDS) followed by adjuvant chemotherapy. Interval debulking surgery after neoadjuvant chemotherapy (NACT-IDS) is a reasonable alternative. Methods: This study was a retrospective review of patients of Stage III/IV EOC treated either by UDS or NACT-IDS between January 2016 and December 2018 to report the comparison of progression-free survival (PFS) and overall survival (OS) of patients with advanced-stage EOC treated with either UDS or NACT-IDS. Results: Out of 50 patients, 19 (38%) underwent UDS, and 31 (62%) received NACT. The mean follow-up duration was 27.7 months. No gross residual disease was achieved in 52.6% of the UDS group and in 70.4% of the NACT-IDS group. The median PFS of 20 and 30 months was observed in the UDS and NACT-IDS groups, respectively (log-rank P = 0.054). The median OS was 36 months in the NACT-IDS group and could not be reached in the UDS group (log-rank P = 0.329). Only residual disease was significantly associated with survival (hazards ratio 3.03, 95% confidence interval: 1.19–7.74) on multivariate Cox regression analysis. Conclusions: In advanced-stage EOC, the survival outcomes of NACT-IDS are comparable with those of UDS. Apart from the patient-specific parameters, the decision for UDS or NACT-IDS should take in account the expertise of the surgeon and the institutional capacity as a whole.Keywords
This publication has 25 references indexed in Scilit:
- Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence— results of a prospective multi-centre studyEuropean Journal of Surgical Oncology, 2021
- Distribution of residual disease in the peritoneum following neoadjuvant chemotherapy in advanced epithelial ovarian cancer and its potential therapeutic implicationsEuropean Journal of Surgical Oncology, 2021
- FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisitedGynecologic Oncology, 2016
- Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer centerGynecologic Oncology, 2016
- Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish studyGynecologic Oncology, 2014
- Staging classification for cancer of the ovary, fallopian tube, and peritoneumInternational Journal of Gynecology & Obstetrics, 2013
- The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma — Analysis of patient data in the prospective OVCAD studyGynecologic Oncology, 2013
- Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?Gynecologic Oncology, 2013
- Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancerGynecologic Oncology, 2011
- Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancerEuropean Journal of Surgical Oncology, 2010